Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Equity Ratio (2019 - 2025)

Historic Equity Ratio for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to 0.74.

  • Beam Therapeutics' Equity Ratio rose 906.64% to 0.74 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.74, marking a year-over-year increase of 906.64%. This contributed to the annual value of 0.66 for FY2024, which is 114.92% down from last year.
  • As of Q3 2025, Beam Therapeutics' Equity Ratio stood at 0.74, which was up 906.64% from 0.75 recorded in Q2 2025.
  • Beam Therapeutics' 5-year Equity Ratio high stood at 0.77 for Q1 2025, and its period low was 0.53 during Q3 2022.
  • In the last 5 years, Beam Therapeutics' Equity Ratio had a median value of 0.61 in 2021 and averaged 0.64.
  • As far as peak fluctuations go, Beam Therapeutics' Equity Ratio tumbled by 2832.35% in 2022, and later skyrocketed by 2297.65% in 2023.
  • Over the past 5 years, Beam Therapeutics' Equity Ratio (Quarter) stood at 0.56 in 2021, then dropped by 2.5% to 0.55 in 2022, then rose by 22.98% to 0.67 in 2023, then fell by 1.15% to 0.66 in 2024, then rose by 10.87% to 0.74 in 2025.
  • Its Equity Ratio was 0.74 in Q3 2025, compared to 0.75 in Q2 2025 and 0.77 in Q1 2025.